SBC Medical Group Holdings Inc Dossier
|
SectorHealth Care IndustryHealth Care Providers & Services Beta (adjusted)0.73 Intrinsic Value $8.33median of 5 methods · middle span $6-$9based on filings through 30 Jun 2026 Market Price $5.07Price as of 1 Oct 2026 Significantly undervaluedIntrinsic value is 64% above the market price −50% · IV below pricenear fair value ±15%IV above price · +50% marker beyond scale (+64%) Data confidence Sign in to view data confidence Market Cap $521.4M Enterprise Value $374.9M Shares Outstanding 102.2M diluted Moat Rating Wide Next Earnings Date12 Nov 2026 All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference. ThesisStreet consensus, scenarios, merits, risks, and invalidation triggers Thesis Summary SBC Medical Group Holdings Inc. operates as a highly profitable Medical Services Organization (MSO) providing comprehensive management support to aesthetic and cosmetic clinics, primarily in Japan. Despite a temporary decline in reported revenues due to a strategic franchise fee restructure implemented in April 2025, the company's underlying business remains exceptionally strong, characterized by high customer retention (72% repeat rate) and robust EBITDA margins exceeding 40%. With a massive net cash position and strategic international expansion underway, the recent stock pullback presents an attractive entry point for investors. This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today. Street view · analyst 12-month targets Low · most bearish analyst$7.00 Mean target$8.50 High · most bullish analyst$10.00 Our research · scenarios, merits, risks, and invalidation triggersResearch as of 19 Jun 2026 Scenarios · 12-month scenario targets Bear CaseDownside scenario $3.0020% Intensifying competition in the Japanese aesthetic market or adverse regulatory changes regarding cosmetic procedures pressure franchise clinic volumes. International expansion efforts in Southeast Asia and the US face execution delays or higher-than-expected customer acquisition costs, dragging down overall profitability. Base CaseCentral scenario $8.5050% Matches the consensus meanThe company successfully returns to positive year-over-year revenue growth in late 2026 as same-clinic sales continue to improve. Domestic clinic operations in Japan remain highly stable, and the company maintains its high-liquidity posture with over $160 million in cash and minimal debt. Valuation multiples expand moderately toward peer averages. Bull CaseUpside scenario $10.0030% Rapid international expansion through direct operations, M&A, and partnerships (such as OrangeTwist in the US) accelerates top-line growth. AI-driven operational transformations significantly lower administrative costs, expanding EBITDA margins beyond 45%. The market quickly recognizes the underlying growth profile as the 2025 fee restructure headwinds fully clear. Scenarios are anchored to street consensus at the research date, with our probabilities and rationale. Key Investment Merits
Key Investment Risks
Thesis Invalidation Triggers
All scenarios are estimates and subject to change. Past performance is not indicative of future results. Quality Pillars MembersThis section is available to registered members. Create a free account or sign in to unlock the full breakdown. Explore this dossierValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework. |